CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 90 enrolled
Drug / intervention
AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02393885
NCT02393885N/ACompleted
CompareCT.gov

Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) Approach for Treatment of Subjects With Persistent or Long Standing Persistent Atrial Fibrillation With Radiofrequency Ablation

AtriCure, Inc.·interventional·Posted Mar 20, 2015·Updated Dec 19, 2024

In Brief

A clinical study evaluating AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation for Atrial Fibrillation and Persistent or Longstanding Persistent Atrial Fibrillation. Completed, enrolled 90 participants across 17 sites in 3 countries.

Detailed Summary

The objective of this study is to establish the safety and effectiveness of a dual epicardial and endocardial ablation procedure for patients presenting with Persistent Atrial Fibrillation or Longstanding Persistent Atrial Fibrillation

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation, Persistent or Longstanding Persistent Atrial Fibrillation
CountriesBelgium, Netherlands, United States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 20, 2015
Enrollment StartFeb 1, 2015
Primary CompletionMar 28, 2022
Study CompletionApr 17, 2024
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 11.3 years ago

Interventions

AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablationdevice